Publications by authors named "W Wijagkanalan"
A reduced-dose recombinant pertussis vaccine booster in Thai adolescents: a phase 2/3, observer-blinded, randomised controlled, non-inferiority trial.
Lancet Child Adolesc Health
December 2024
Background: A resurgence of pertussis has increased the demand for low-cost vaccines. The aim of this study was to test the immunogenicity of a booster acellular monovalent pertussis vaccine containing reduced-dose (2 μg) recombinant pertussis toxin (PT) and 5 μg filamentous haemagglutinin (FHA; ap) against a version of ap containing tetanus and reduced-dose diphtheria toxoids (Tdap) and a licensed vaccine containing chemically detoxified PT and FHA combined with tetanus toxoid and reduced-dose diphtheria toxoid (Tdap).
Methods: This phase 2/3, observer-blinded, randomised, controlled, non-inferiority trial was done in adolescents aged 9-17 years at two clinical research centres in Bangkok and Pathum Thani, Thailand.
Article Synopsis
- Pertussis toxin (PT) is crucial for vaccine and natural immunity against infections, but its neutralizing epitopes have not been structurally characterized until now.
- Researchers used cryo-electron microscopy to visualize genetically detoxified PT (PTg) bound to two neutralizing antibodies, revealing how these antibodies prevent PT from adhering to cells and performing its toxic function.
- The study identifies key structural elements of PT that are vital for vaccine design, enhancing our understanding of immune protection and paving the way for more effective PT-based immunogens.
Aim/objective: This study investigates placental antibody transfer following recombinant pertussis vaccination in pregnancy in a real-world setting.
Methods: This postmarketing observational study recruited pregnant women vaccinated with monovalent recombinant acellular pertussis (aP) vaccine (aP; n = 199) or combined to tetanus-diphtheria (TdaP; n = 200), or Td-vaccine only (n = 54). Pregnancy, delivery, and neonatal outcomes were assessed.
ChulaCov19 mRNA vaccine demonstrated promising phase 1 results. Healthy adults aged 18-59 years were double-blind randomised 4:1 to receive two intramuscular doses of ChulaCov19 50 µg or placebo. Primary endpoints were safety and microneutralization antibody against-wild-type (Micro-VNT50) at day 50.
View Article and Find Full Text PDFEstablishment of an mRNA vaccine platform in low- and middle-income countries (LMICs) is important to enhance vaccine accessibility and ensure future pandemic preparedness. Here, we describe the preclinical studies of "ChulaCov19", a SARS-CoV-2 mRNA encoding prefusion-unstabilized ectodomain spike protein encapsulated in lipid nanoparticles (LNP). In female BALB/c mice, ChulaCov19 at 0.
View Article and Find Full Text PDF